Phase II trial of clofarabine with topotecan, vinorelbine, and thiotepa in pediatric patients with relapsed or refractory acute leukemia

Pediatric Blood and Cancer

Volumn 61, Issue 3, 2014, Pages 431-435

  Shukla, Neerav ^a   Kobos, Rachel ^a   Renaud, Thomas ^a   Steinherz, Laurel J ^a   Steinherz, Peter G ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Clofarabine; Leukemia; Pediatric; Refractory; Relapsed

Indexed keywords

AMINOTRANSFERASE; CLOFARABINE; CYTARABINE; DEXAMETHASONE; HYDROCORTISONE; NAVELBINE; THIOTEPA; TOPOTECAN;

ACUTE BIPHENOTYPIC LEUKEMIA; ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; ALPHA HEMOLYTIC STREPTOCOCCUS; ARTICLE; CAPILLARY LEAK SYNDROME; CENTRAL NERVOUS SYSTEM DISEASE; CHILD; CHILDHOOD LEUKEMIA; CLINICAL ARTICLE; COAGULASE NEGATIVE STAPHYLOCOCCUS; CONTINUOUS INFUSION; DISEASE COURSE; ESCHERICHIA COLI; FEBRILE NEUTROPENIA; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; INFANT; LISTERIA MONOCYTOGENES; MALE; MAXIMUM TOLERATED DOSE; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRE B LYMPHOCYTE; PRESCHOOL CHILD; PRIORITY JOURNAL; PROPHYLAXIS; PSEUDOMONAS AERUGINOSA; REFRACTORY ACUTE LEUKEMIA; RELAPSED ACUTE LEUKEMIA; SCHOOL CHILD; VANCOMYCIN RESISTANT ENTEROCOCCUS; YOUNG ADULT;

CLOFARABINE; LEUKEMIA; PEDIATRIC; REFRACTORY; RELAPSED;

ADENINE NUCLEOTIDES; ADOLESCENT; ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ARABINONUCLEOSIDES; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; INFANT; LEUKEMIA, MYELOID, ACUTE; MALE; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; RECURRENCE; THIOTEPA; TOPOTECAN; VINBLASTINE;

EID: 84892546430     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.24789     Document Type: Article

References (24)

1. Pui CH, Mullighan CG, Evans WE, et al. Pediatric acute lymphoblastic leukemia: Where are we going and how do we get there? Blood 2012; 120:1165-1174.
2. Rubnitz JE, Inaba H. Childhood acute myeloid leukaemia. Br J Haematol 2012; 159:259-276.
3. Gaynon PS, Childhood acute myeloid leukaemia. Br J Haematol 2005; 131:579-587.
4. Sander A, Zimmermann M, Dworzak M, et al. Consequent and intensified relapse therapy improved survival in pediatric AML: Results of relapse treatment in 379 patients of three consecutive AML-BFM trials. Leukemia 2010; 24:1422-1428.
5. Oliansky DM, Camitta B, Gaynon P, et al. Role of cytotoxic therapy with hematopoietic stem cell transplantation in the treatment of pediatric acute lymphoblastic leukemia: Update of the 2005 evidence-based review. Biol Blood Marrow Transplant 2012; 18:505-522.
6. Bonate PL, Arthaud L, Cantrell WR Jr, et al. Discovery and development of clofarabine: A nucleoside analogue for treating cancer. Nat Rev Drug Discov 2006; 5:855-863.
7. Parker WB, Shaddix SC, Chang CH, et al. Effects of 2-chloro-9-(2-deoxy-2-fluoro-beta-d-arabinofuranosyl)adenine on K562 cellular metabolism and the inhibition of human ribonucleotide reductase and DNA polymerases by its 5′-triphosphate. Cancer Res 1991; 51:2386-2394.
8. Jeha S, Gandhi V, Chan KW, et al. Clofarabine, a novel nucleoside analog, is active in pediatric patients with advanced leukemia. Blood 2004; 103:784-789.
9. Jeha S, Gaynon PS, Razzouk BI, et al. Phase II study of clofarabine in pediatric patients with refractory or relapsed acute lymphoblastic leukemia. J Clin Oncol 2006; 24:1917-1923.
10. Jeha S, Razzouk B, Rytting M, et al. Phase II study of clofarabine in pediatric patients with refractory or relapsed acute myeloid leukemia. J Clin Oncol 2009; 27:4392-4397.
11. Miano M, Pistorio A, Putti MC, et al. Clofarabine, cyclophosphamide and etoposide for the treatment of relapsed or resistant acute leukemia in pediatric patients. Leuk Lymphoma 2012; 53:1693-1698.
12. Inaba H, Bhojwani D, Pauley JL, et al. Combination chemotherapy with clofarabine, cyclophosphamide, and etoposide in children with refractory or relapsed haematological malignancies. Br J Haematol 2012; 156:275-279.
13. Abd Elmoneim A, Gore L, Ricklis RM, et al. Phase I dose-escalation trial of clofarabine followed by escalating doses of fractionated cyclophosphamide in children with relapsed or refractory acute leukemias. Pediatr Blood Cancer 2012; 59:1252-1258.
14. Inaba H, Rubnitz JE, Coustan-Smith E, et al. Phase I pharmacokinetic and pharmacodynamic study of the multikinase inhibitor sorafenib in combination with clofarabine and cytarabine in pediatric relapsed/refractory leukemia. J Clin Oncol 2011; 29:3293-3300.
15. Hijiya N, Thomson B, Isakoff MS, et al. Phase 2 trial of clofarabine in combination with etoposide and cyclophosphamide in pediatric patients with refractory or relapsed acute lymphoblastic leukemia. Blood 2011; 118:6043-6049.
16. Steinherz PG, Shukla N, Kobos R, et al. Remission re-induction chemotherapy with clofarabine, topotecan, thiotepa, and vinorelbine for patients with relapsed or refractory leukemia. Pediatr Blood Cancer 2010; 54:687-693.
17. Locatelli F, Testi AM, Bernardo ME, et al. Clofarabine, cyclophosphamide and etoposide as single-course re-induction therapy for children with refractory/multiple relapsed acute lymphoblastic leukaemia. Br J Haematol 2009; 147:371-378.
18. Hijiya N, Gaynon P, Barry E, et al. A multi-center phase I study of clofarabine, etoposide and cyclophosphamide in combination in pediatric patients with refractory or relapsed acute leukemia. Leukemia 2009; 23:2259-2264.
19. Cooper TM, Razzouk BI, Gerbing R, et al. Phase I/II trial of clofarabine and cytarabine in children with relapsed/refractory acute lymphoblastic leukemia (AAML0523): A report from the Children's Oncology Group. Pediatr Blood Cancer 2013; 60:1141-1147.
20. Cooper T, Alonzo TA, Gerbing R, et al. AAM L0523: A report from the Children's Oncology Group on the efficacy of clofarabine in combination with cytarabine in pediatric patients with relapsed acute myeloid leukemia. The American Society of Hematology 53rd annual meeting 2012 (3604) 2012.
21. Kolb EA, Steinherz PG. A new multidrug reinduction protocol with topotecan, vinorelbine, thiotepa, dexamethasone, and gemcitabine for relapsed or refractory acute leukemia. Leukemia 2003; 17:1967-1972.
22. Lipshultz SE, Lipsitz SR, Sallan SE, et al. Chronic progressive cardiac dysfunction years after doxorubicin therapy for childhood acute lymphoblastic leukemia. J Clin Oncol 2005; 23:2629-2636.
23. Steinherz LJ, Steinherz PG, Tan CT, et al. Cardiac toxicity 4 to 20 years after completing anthracycline therapy. JAMA 1991; 266:1672-1677.
24. Wells RJ, Adams MT, Alonzo TA, et al. Mitoxantrone and cytarabine induction, high-dose cytarabine, and etoposide intensification for pediatric patients with relapsed or refractory acute myeloid leukemia: Children's Cancer Group Study 2951. J Clin Oncol 2003; 21:2940-2947.